The FDA approved various checkpoint inhibitors as cancer treatments, including mAbs that target PD-1, such as nivolumab (Opdivo®), pembrolizumab (Keytruda®), and cemiplimab (Libtayo®); mAbs against PD-L1, such as atezolizumab (Tecentriq®), avelumab (Bavencio®), and durvalumab (Imfinzi®); and anti-CTLA-4 mAb ipilimumab (Yervoy®). Here, CD274 is linked to cancer.